Introduction
============

Tigecycline, formerly GAR-936 (Tygacil^®^; Wyeth Pharmaceuticals, Inc., Philadelphia, PA, USA), is a glycylcycline antimicrobial currently approved by the Food and Drug Administration (FDA) for the treatment of complicated intra-abdominal infections (cIAIs) and complicated skin and skin structure infections (cSSSIs) ([@b124]). In addition to its broad spectrum in vitro activity against Gram-positives, Gram-negatives and anerobes, tigecycline demonstrates activity in vitro against MRSA, VRE, and ESBL-producing organisms ([@b124]). Therefore, it has potential applications in the management of polymicrobial infections or those due to resistant organisms.

Two of the most prevalent bacterial infections in clinical practice are cSSSIs and cIAIs. For example, surgical site infections are estimated to occur 500,000 times per year among the 27 million surgical procedures performed ([@b19]). Studies evaluating the impact of surgical site infections have demonstrated that these infections are consistently associated with an increase in healthcare costs, prolonged hospitalizations, and an increase in morbidity and mortality ([@b119]; [@b61]). Specifically, one study, evaluating cSSSI following hip replacement surgeries, found a median increased length of stay of 32.5 days directly related to the cSSSI; additionally, the morbidity rate associated with the cSSSI was 14.3% ([@b70]). Similarly, the incidence of cIAIs is also difficult to determine because of its inclusion of a broad range of diagnoses. Among these, complicated appendicitis may occur in up to 30% of appendicitis cases ([@b34]). Additionally, cIaIs account for considerable hospital cost ([@b99]). Inappropriate treatment has been associated with both treatment failures as well as increased mortality ([@b99]). For example, [@b107] found a clinical failure rate of 35.7% and a mortality rate of 10.7% among patients receiving initial inappropriate therapy with intraabdominal infections.

Effective management of both cIAIs and cSSSIs require the timely institution of appropriate antimicrobital therapy and, in select cases, surgical interventions ([@b99]; [@b105]). However, increases in antibiotic resistance seen in bacteria commonly causing such infections has made selection of appropriate empiric therapy challenging ([@b10]; [@b69]). Data recently published from a worldwide multi-center longitudinal antimicrobial resistance tracking program, the SENTRY Antimicrobial Surveillance Program, reported rates of methicillin-resistant *Staphylococcus aureus* (MRSA) causing skin and skin structure infections ranging from 22.8% in Europe to 35.9% in North America ([@b69]). Isolation of vancomycin-resistant enterococci (VRE) ranged from 3.6% in Europe to 12.2% in North America. Furthermore, Gram-negative organisms have also demonstrated diminished susceptibility. For example, reported rates of multidrug-resistant *Pseudomonas aeruginosa* and extended-spectrum beta-lactamase (ESBL) producing *Klebsiella* spp. were 3.2% and 11.3% in North America, and 24.7% and 48.0% in Latin America, respectively. ESBL-producing *Escherichia coli* rates ranged from 6.6% in North America to 15.1% in Latin America ([@b69]).

Rates of resistant organisms isolated in patients with cIAIs are also increasing. In vitro susceptibilities for over 7,000 *E. coli* isolates from patients with intra-abdominal infections varied according to geographic region ([@b10]). The rate of ESBL-producing *E. coli* worldwide was 8.9% from 2002--2004, with the highest rates in the Asia/Pacific region (16.6%) ([@b10]).

The purpose of this article is to review the in vitro activity, pharmacokinetics, pharmacodynamics and clinical efficacy and safety of tigecycline for the treatment of cIAIs and cSSSIs. Tigecycline's role in therapy will also be discussed.

Overview of tigecycline
=======================

Pharmacology
------------

Tigecycline (C~29~H~39~N~5~O~8~) is the first of a new class of antimicrobials called glycylcyclines, which are related to the tetracycline class ([@b124]). Although structurally similar to minocycline, it differs primarily by the presence of a side chain addition at position 9 ([Figure 1](#fig1){ref-type="fig"}). Tigecycline possesses a similar mechanism of action to tetracyclines in that it binds to the bacterial 30S ribosomal subunit, thereby inhibiting bacterial protein synthesis ([@b8]). However, the binding affinity for tigecycline to this ribosomal site is approximately 5 times that of tetracyclines ([@b8]). Tigecycline also demonstrates 70S ribosomal subunit binding, with up to 100-fold greater affinity as compared with tetracycline ([@b78]).
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Resistance to the tetracycline class most frequently involves protection of the ribosome and/or efflux pumps ([@b23]; [@b104]; [@b8]) Binding to the 30S ribosomal subunit is thought to prevent ribosomal protection ([@b86]; [@b111]; [@b84]; [@b24]; [@b125]). Efflux pumps are responsible for expelling drug from the intracellular to extracellular space, thus preventing action of the drug and therefore causing resistance ([@b65]; [@b82]; [@b62]; [@b1]; [@b68]; [@b122]; [@b35]). In contrast to tetracyclines, tigecycline is not usually affected by efflux pumps. However, tigecycline is susceptible to efflux pumps of the "resistance nodulation division" (RND) which are common among *P. aeruginosa* ([@b84]); tigecycline is a know substrate for the pumps, described as MexAB-OprM, MexCD-OprJ, MexEF-OprN and MexXY-OprM ([@b35]). While *Acinetobacter baumannii* is generally sensitive to tigecycline, it can possess 2 of these RND pumps. Therefore, although further study is needed, emerging resistance to tigecycline while on therapy may be a concern for this organism ([@b90]). Tigecycline appears to be unaffected by other mechanisms of resistance, including enzyme target changes and target site modifications. Production of beta-lactamases (including ESBLs) also do not influence tigecycline's antimicrobial activity ([@b124]).

Microbiology
------------

The Clinical and Laboratory Standards Institute (CLSI) has set the tigecycline in vitro minimum inhibitory concentration (MIC) susceptibility breakpoints for *Streptococcus* spp. (excluding *S. pneumoniae*) and *Enterococcus faecalis* (vancomycin-susceptible organisms) at ≤0.25 μg/mL. MIC breakpoints to be considered susceptible to tigecycline for *S. aureus* (including both MSSA and MRSA) are ≤0.5 μg/mL, while Enterobacteriaceae and anaerobes are set at ≤2 μg/mL and ≤4 μg/mL, respectively ([@b26], [@b27], [@b28], [@b29]; [@b124]). The European Committee on Antimicrobial Susceptibility Testing (EUCAST) susceptibility breakpoint for Enterobacteriaceae however, is ≤1 μg/mL, and breakpoints have not been established for anaerobes ([@b113]).

Tigecycline displays excellent in vitro activity against most Gram-positive organisms ([@b95]). A recent study evaluating 26,474 bloodstream infection isolates from 6 different continents found 99.4% (n = 8765) of *S. aureus* isolates susceptible with an MIC~90~ = 0.5 μg/mL (range of ≤0.016--1 μg/mL) ([@b95]). In this same study, 92.7% (n = 3258) of *Enterococcus* spp. were considered sensitive to tigecycline, with an MIC~90~ of 0.25 μg/mL (range of ≤0.016--2 μg/mL). Over 97 % (n = 605) of *S. pneumoniae* and viridans group *streptococci* (n = 378) were also considered susceptible, with MIC~90~ of ≤0.12 μg/mL (range ≤0.12--1 μg/mL) and ≤0.12 μg/mL (range ≤0.12--0.5 μg/mL), respectively ([@b95]).

In general, tigecycline demonstrated activity against Gram-positive bacteria resistant to other classes of antibiotics. Susceptibility of *S. aureus* to tigecycline appears to be independent of oxacillin susceptibility ([@b95]). In addition, a vancomycin-resistant *S. aureus* strain (VRSA) isolated at Hershey Medical Center demonstrated an MIC of 0.125 μg/mL to tigecycline ([@b12]). Tigecycline also has potent in vitro activity against quinolone-resistant *S. pneumoniae*, with a reported MIC of 0.12 μg/mL ([@b49]). For vancomycin-resistant *E. faecium* (n = 77) and vancomycin-resistant *E. faecalis* (n = 11), the MIC~90~ were 0.06 μg/mL and 0.12 μg/mL, respectively with 100% susceptibility in both species ([@b57]).

Tigecycline has shown potent *in vitro* activity against most Gram-negative organisms, with the exception of *Proteus* (n = 320) and *Pseudomonas* spp. (n = 1,338) with MIC~90~ (and ranges) of 4 μg/mL (0.25--16 μg/mL) and \>32 mg/mL (0.008--≥32 μg/mL), respectively ([@b95]). *E. coli* (n = 3217) and *Klebsiella* spp. (n = 1,503) are also susceptible to tigecycline. The MIC~90~ (and ranges) of 0.25 g/mL (0.03--4 μg/mL) and 1 μg/mL (0.06--8 μg/mL) have been reported for these organisms, respectively ([@b95]). Tigecycline also demonstrates activity against ESBL-producing strains of these pathogens. MIC~90~ (range) values for 142 ESBL-producing *E. coli* isolates and 278 ESBL-producing *K. pneumoniae* isolates were 1 μg/mL (0.25--2 μg/mL) and 2 μg/mL (0.25--8 μg/mL), respectively ([@b14]). MICs ranging 0.03--8 μg/mL and an MIC~90~ of 1 μg/mL was reported in the largest published study of *Acinetobacter* spp. isolates (n = 851) to date ([@b120]). While several other in vitro studies have reported a high percentage of *Acinetobacter* spp. susceptible MICs according to CLSI criteria, many of these organisms would be considered resistant if utilizing EUCAST criteria ([@b13], [@b14]; [@b95]; [@b120]). Tigecycline also remains active against carbapenem-resistant *A. baumannii* and pan-resistant *A. baumannii* according to 2 recent case reports, although tigecycline-resistant *A. baumanii* has emerged clinically ([@b11]; [@b109]; [@b79]).

Anaerobic activity of tigecycline has been studied in several clinical trials in which the results are summarized in a study by Bradford et al ([@b15]). Results from these studies demonstrate tigecycline's potent anaerobic activity against *Clostidium perfringens, Propionibacterium acnes*, and *Bacteroides fragilis.* MICs for these organisms were below the CLSI susceptibility breakpoint of ≤4 μg/mL ([@b15]). [Table 1](#tbl1){ref-type="table"} describes further the in vitro susceptibilities of tigecycline.

###### 

In vitro susceptibilities of select aerobic and anaerobic organisms to tigecycline[a](#tf1-1){ref-type="table-fn"}

  Organism                                      No. of isolates   MIC90[b](#tf1-2){ref-type="table-fn"}   MIC range[b](#tf1-2){ref-type="table-fn"}   \% Susceptible[c](#tf1-3){ref-type="table-fn"}   References
  --------------------------------------------- ----------------- --------------------------------------- ------------------------------------------- ------------------------------------------------ ------------
  *Staphylococcus aureus*                       8765              0.5                                     ≤0.016--1                                   99.4                                             ([@b95])
   MSSA                                         813               0.12                                    0.015--0.5                                  100                                              ([@b120])
   MRSA                                         879               0.25                                    0.03--0.5                                   100                                              ([@b120])
   VISA                                         19                0.5                                     0.06--1                                     NA[d](#tf1-4){ref-type="table-fn"}               ([@b80])
  Staphylococci, coagulase-negative (CoNS)      3570              0.5                                     ≤0.016--2                                   97.5                                             ([@b95])
  CoNS, methicillin susceptible                 71                0.5                                     0.03--1                                     NA[d](#tf1-4){ref-type="table-fn"}               ([@b46])
  CoNS, methicillin resistant                   189               0.5                                     ≤0.12--2                                    NA[d](#tf1-4){ref-type="table-fn"}               ([@b46])
  *S. pneumoniae*                               605               ≤0.12                                   ≤0.12--1                                    \--[e](#tf1-5){ref-type="table-fn"}              ([@b95])
   *S. pneumoniae*, penicillin susceptible      279               0.5                                     NA[d](#tf1-4){ref-type="table-fn"}          NA[d](#tf1-4){ref-type="table-fn"}               ([@b57])
   *S. pneumoniae*, penicillin-resistant        54                0.25                                    NA[d](#tf1-4){ref-type="table-fn"}          NA[d](#tf1-4){ref-type="table-fn"}               ([@b57])
  Streptococci, β-hemolytic                     769               ≤0.12                                   ≤0.12--0.5                                  99.7                                             ([@b95])
  Streptococci, viridans group                  378               ≤0.12                                   ≤0.12--0.05                                 98.1                                             ([@b95])
  Enterococci spp.                              3258              0.25                                    ≤0.016--2                                   92.7                                             ([@b95])
   *Enterococcus spp.*-vancomycin susceptible   466               0.5                                     ≤0.12--1                                    NA[d](#tf1-4){ref-type="table-fn"}               ([@b46])
  *Enterococcus spp.*-vancomycin resistant      39                0.25                                    0.03--0.5                                   NA[d](#tf1-4){ref-type="table-fn"}               ([@b46])
  Nocardia spp.                                 51                4                                       ≤0.06--8                                    NA[d](#tf1-4){ref-type="table-fn"}               ([@b21])
  *Escherichia coli*                            3217              0.25                                    0.03--4                                     \>99.9                                           ([@b95])
   ESBL-producing *E.coli*                      115               0.38                                    0.047--0.75                                 NA[d](#tf1-4){ref-type="table-fn"}               ([@b103])
  *Klebsiella pneumonia*                        1334              2                                       ≤0.008--8                                   95                                               ([@b120])
   ESBL-producing                               126               2                                       0.12--8                                     92.1                                             ([@b120])
  *K. pneumoniae*                                                                                                                                                                                      
  *Klebsiella oxytoca*                          248               1                                       0.06--4                                     98.8                                             ([@b120])
  *Enterobacter aerogenes*                      419               1                                       0.06--8                                     95.7                                             ([@b120])
  *Enterobacter cloacae*                        1089              2                                       ≤0.008--8                                   93                                               ([@b120])
  *Haemophilus influenzae*                      336               0.25                                    NA[d](#tf1-4){ref-type="table-fn"}          \--[e](#tf1-5){ref-type="table-fn"}              ([@b57])
   *H. influenzae*, β-lactamase positive        93                0.25                                    NA[d](#tf1-4){ref-type="table-fn"}          \--[e](#tf1-5){ref-type="table-fn"}              ([@b57])
  *Moraxella catarrhalis*                       54                0.5                                     NA[d](#tf1-4){ref-type="table-fn"}          \--[e](#tf1-5){ref-type="table-fn"}              ([@b48])
  *Serratia marscens*                           658               1                                       0.012--8                                    97                                               ([@b120])
  Citrobacter spp.                              252               0.5                                     NA[d](#tf1-4){ref-type="table-fn"}          86.9                                             ([@b47])
  *Acinetobacter baumannii*                     851               1                                       0.03-8                                      \--[e](#tf1-5){ref-type="table-fn"}              ([@b120])
  *Pseudomonas aeruginosa*                      1338              ≥32                                     ≤0.008--≥32                                 \--[e](#tf1-5){ref-type="table-fn"}              ([@b120])
  *Stenotrophomonas maltophilia*                203               2                                       0.12--8                                     \--[e](#tf1-5){ref-type="table-fn"}              ([@b95])
  *Burkholderia cepacia*                        21                16                                      0.25--32                                    \--[e](#tf1-5){ref-type="table-fn"}              ([@b22])
  *Campylobacter jejuni*                        108               4                                       0.12--16                                    \--[e](#tf1-5){ref-type="table-fn"}              ([@b91])
  *Campylobacter coli*                          8                 16                                      0.5--16                                     \--[e](#tf1-5){ref-type="table-fn"}              ([@b91])
  *Proteus mirabilis*                           320               4                                       0.25--16                                    46.9                                             ([@b95])
  *Bacteroides fragilis*                        2721              8                                       0.06--32                                    94.9                                             ([@b98])
  *Bacteroides fragilis group*                  5225              8                                       0.06--64                                    95.7                                             ([@b98])
   *B. distasonis*                              274               8                                       0.25--32                                    97.9                                             ([@b98])
   *B. ovatus*                                  545               8                                       0.125--16                                   96.7                                             ([@b98])
   *B. thetaiotaomicron*                        978               8                                       0.25--32                                    96.4                                             ([@b98])
   *B. vulgatus*                                306               4                                       0.25--16                                    98.4                                             ([@b98])
  *C. perfringens*                              51                1.0                                     ≤0.06--2                                    NA[d](#tf1-4){ref-type="table-fn"}               ([@b15])
  *Clostridium difficile*                       12                0.06                                    0.06                                        NA[d](#tf1-4){ref-type="table-fn"}               ([@b52])
  *Fusobacterium varium*                        13                0.25                                    0.06--0.25                                  NA[d](#tf1-4){ref-type="table-fn"}               ([@b52])
  Lactobacillus spp.                            15                0.5                                     0.06--1                                     NA[d](#tf1-4){ref-type="table-fn"}               ([@b52])

Adapted with permission from ([@b115]. Tigecycline: a new glycylcycline antimicrobial. *Int J Clin Pract*, 60:1662--72. Blackwell Publishing.)

MIC = minimum inhibitory concentration.

According to CLSI criteria.

NA = not available.

No CLSI criteria available.

Pharmacokinetics
----------------

Tigecycline exhibits linear kinetics following intravenous (IV) administration ([@b71]). Data from 103 healthy adult volunteers who received tigecycline intravenously (100 mg followed by 50 mg every 12 hours over 60 minutes) produced steady state maximum plasma concentrations (C~max~) and minimum plasma concentrations (C~min~) of 0.63 μg/mL and 0.13 μg/mL, respectively. The area under the plasma concentration-time curve from 0 to 24 hours (AUC~0--24~) was 4.70 μg·h/mL ([@b71]; [@b124]). Patients with cSSSIs (n = 81) participating in a phase II study demonstrated pharmacokinetic parameters similar to healthy adult volunteers, with a C~max~ of 0.403 μg/ml and AUC~0--12~ of 2.24 μg·h/mL ([@b83]).

Tigecycline is highly protein bound (71%--89%) at plasma drug concentrations achieved in clinical trials (0.1--1.0 μg/mL) ([@b124]). The volume of distribution of tigecycline reported from healthy volunteer studies is 7--10 L/kg ([@b71]). Based on animal and human studies, tigecycline can distribute into various bodily fluids and tissues, such as the lungs, skin, peritoneal fluid, gall bladder, colon, heart, liver, meninges and bone ([@b114]; [@b93]; [@b33]; [@b53]; [@b108]; [@b92]; [@b97]; [@b124]). In adults undergoing medical or surgical procedures (n = 104), serum, tissue, and body fluid concentrations of tigecycline were evaluated following a single dose of 100 mg of tigecycline administered over 30 minutes ([@b92]). The mean ratio of tigecycline in the tissue to serum (expressed as AUC~0--24~) was 537 in the bile, 23 for the gall bladder, 2.6 for the colon, and 2.0 for the lung ([@b92]). The highest concentration of tigecycline was found in the bile, which is consistent with the drug's known route of elimination. Additionally, lower tissue to serum concentrations were achieved in the bone, synovial fluid, and cerebrospinal fluid (CSF). The mean ratio of tigecycline in the tissue to serum (expressed as AUC~0--24~) was 0.41 for the bone, 0.31 for the synovial fluid, and 0.11 for the CSF. The highest CSF to serum ratios occurred approximately 24 hours after infusion. Of note, bone penetration of tigecycline in animal models was higher than what was achieved in this human study ([@b114]; [@b92]). The inconsistency of bone penetration in this study versus previous animal studies may have been due to poor extraction techniques, tight binding of the drug to bone, or the single dose design of the study. Additionally, peritoneal fluid penetration of tigecycline has been reported in a critically ill patient. The extrapolated penetration into the peritoneal fluid was about 50% ([@b97]). Tigecycline has also been shown to have a 74% (mean) penetration into cantharidin-induced blisters in healthy volunteers (n = 10) ([@b108]).

Tigecycline is not extensively metabolized. The main metabolic pathway of tigecycline is glucuronidation. Non-active metabolites that were recovered in the urine and feces include a glucuronide, its epimer (M1 and M2), and N-acetyl-9-aminominocycline (M6) ([@b58]; [@b88]; [@b124]). The pharmacokinetic model of tigecycline follows a 2-compartment model with first-order elimination based on pooled data from Phase II and III studies involving patients with cSSSIs and cIAIs ([@b118]). The primary route of elimination of tigecycline is through feces and the biliary tract (59%) as unchanged drug and metabolites. Secondary routes of elimination include glucuronidation and renal excretion (33%). Renal excretion only accounts for about 10%--15% of the systemic clearance of tigecycline ([@b58]; [@b71]). The terminal half-life of tigecycline is 37--67 hours and the total systemic clearance is 0.2--0.3 L/h/kg ([@b71]).

Pharmacodynamics
----------------

Tigecycline demonstrates time-dependent bacteriostatic activity in vitro ([@b117]; [@b87]). Its post-antibiotic effect against Gram-negative organisms ranges from 2 to 5 hours, and 8.9 hours for *S. pneumoniae* ([@b117]; [@b87]). Recent animal and clinical data suggests the area-under-the concentration-time curve (AUC) to MIC ratio (AUC/MIC) may be a reliable predictor for efficacy with tigecycline ([@b66]; [@b49]; [@b67]). The AUC/MIC ratios described in the literature for in vitro activity range from 79--158 when evaluating quinolone-resistant *S. pneumoniae*, MRSA and VRE ([@b49]). In a study by Meagher and colleagues ([@b67]), cSSSI patients with *S.aureus* and streptococci as the primary organisms were evaluated to determine the pharmacodynamic properties of tigecycline. Based on the results of this study, the AUC/MIC ratio of 17.9 or higher was a significant predictor of both microbiological and clinical response in cSSSI patients ([@b67]). Although the AUC/MIC ratios range in the literature depending on the organism and infection, no consensus to date has been reached to determine the ideal AUC/MIC ratio for particular disease states.

Special populations
-------------------

Tigecycline's pharmacokinetic profile appears to be independent of age, ethnic backgrounds (African-American, Hispanic, Asian, and Caucasian), and gender. ([@b66]; [@b71]). Patients with renal impairment (creatinine clearance of \<30 mL/min or hemodialysis-dependent) had a non-significant increase in C~max~ and AUC in comparison to healthy volunteers ([@b116]). Additionally, tigecycline was not found to be significantly removed via hemodialysis. Therefore, no dosing adjustments are necessary in patients with renal dysfunction or who are hemodialysis dependent ([@b116]; [@b124]). In contrast to patients with renal dysfunction, patients with severe hepatic impairment (ie, Child-Pugh Class C) had a 43% increase in tigecycline's half-life and a 55% reduction in drug clearance ([@b96]). Thus, it is recommended in these patients that the maintenance dose of tigecycline be reduced to 25 mg every 12 hours in patients with severe hepatic insufficiency ([@b124]). No adjustments are needed for patients with mild to moderate hepatic impairment (Child-Pugh Class A or B) ([@b124]). Pharmacokinetic studies are currently lacking in obese/low-body-weight individuals, the pediatric population, and patients who are lactating or pregnant.

Drug interactions
-----------------

To date, no significant drug-drug interactions have been reported with tigecycline. Tigecycline is not metabolized by the cytochrome P450 system and as a result, it does not alter the metabolism of drugs that go through this system nor do these drugs affect the concentration of tigecycline ([@b124]). Studies evaluating the concurrent administration of tigecycline with either digoxin or warfarin in healthy adults have not demonstrated a significant drug-drug interaction between tigecycline and either of these drugs ([@b126]; [@b85]; [@b124]; [@b127]). However, the manufacturer of tigecycline does recommend that the international normalized ratio (INR) as well as signs and symptoms of bleeding be routinely assessed when tigecycline is administered with warfarin ([@b124]).

Safety and tolerability
-----------------------

Overall, tigecycline was well-tolerated in phase III clinical studies with only 5% of patients discontinuing therapy due to adverse events in comparison to 4.7% in the comparator arms (vancomycin-aztreonam 5.3% and imipenem-cilastatin 4.4%) ([@b4]; [@b41]; [@b124]).

The most common adverse events associated with the administration of tigecycline in phase II and III studies was mild to moderate nausea and vomiting. This occurred most often during the first 2 days of drug therapy, and was the most common reason for discontinuing drug therapy ([@b83]; [@b77]; [@b4]; [@b16]; [@b45]; [@b71]; [@b71]; [@b94]; [@b124]). The incidence of nausea was 34.5% (versus 8.2% in vancomycin-aztreonam; p \< 0.001) in the cSSSIs studies and 24.4% (versus 19% in imipenem-cilastatin; p = 0.01) in the cIAIs studies. The incidence of vomiting was 19.6% (versus 3.6% in vancomycin-aztreonam; p \< 0.001) and 19.2% (versus 14.3% in imipenem-cilastatin; p = 0.008) in cSSSIs and cIAIs studies, respectively ([@b77]; [@b4]; [@b45]; [@b16]; [@b41]). The exact mechanism of tigecycline-induced nausea and vomiting remains unknown, but it is not related to the release of serotonin in the gastrointestinal tract ([@b71]). Nausea and vomiting has occurred more frequently at higher doses and in patients \<50 years of age, female, and non-European descent ([@b71]; [@b124]). While coadministration of food may potentially improve the tolerability of tigecycline, altering the rate of infusion has not been successful in deceasing the incidence of nausea and vomiting ([@b71]). Likewise, administration of antiemetics (such as prochlorperazine, ondansetron, or metoclopramide) does not significantly alter the incidence of nausea and vomiting ([@b71]; [@b124]). During phase III clinical studies, diarrhea was reported in 12.7% of patients receiving tigecycline ([@b124]). However, there were no published cases of *Clostridium difficile* associated diarrhea in these clinical studies ([@b4]; [@b41]; [@b124]).

Tigecycline's ability to induce *C. difficile* infections has also been evaluated ([@b5]). In a human gut model involving 2 epidemic strains of *C. difficile*, the gut flora was significantly decreased although the *C. difficile* spores did not "proliferate"; in addition, cytotoxin was not produced ([@b5]). This seems to correlate clinically, as only limited cases of *C. difficile* infections have been reported with tigecycline to date ([@b123]). However, as with all antimicrobials, tigecycline can theoretically predispose a patient to a *C. difficile* infection.

Due to the structural similarities between tetracyclines and tigecycline, cross-reactivity may occur between these two classes of drugs, and caution should be used in patients with known hypersensitivity reactions to tetracyclines ([@b125]; [@b124]). Furthermore, similar side effects may exist between tetracyclines and tigecycline such as photosensitivity reactions, pancreatitis, and tooth discoloration in children under 8 years old ([@b125]; [@b124]). Long-term safety has not been published with the use of tigecycline to date.

Clinical efficacy
=================

Complicated intra-abdominal infections
--------------------------------------

As with any type of infection, the objectives for the treatment of cIAI are to minimize the time to clinical improvement, prevent recurrence, and eradicate the causative microorganisms. As with most infections, healthcare-associated infectious diseases generally require broader antibacterial coverage for such resistant organisms as*P. aerunginosa, Enterobacter* spp. and MRSA as compared with community-associated infections ([@b99]).

Guidelines published by the Infectious Diseases Society of America for the treatment of cIAIs describe the use of a single-agent, broad-spectrum antimicrobial agent or the use of a combination of antibiotics with activity against common enteric flora ([@b99]). They summarize data from numerous trials. For example, monotherapy for the treatment of cIAIs studied in randomized, prospective clinical trials include the β-lactam/β-lactamase inhibitors such as ampicillin/sulbactam, piperacillin/tazobactam, and ticarcillin/clavulanic acid ([@b40]; [@b121]; [@b39]; [@b60]; [@b2]; [@b76]; [@b30]). The carbapenems (ertapenem, imipenem/cilastatin and meropenem) as well as certain cephalosporins (ceftotetan and cefoxitin) have also been studied ([@b81]; [@b18]; [@b40]; [@b17]; [@b32]; [@b50]; [@b59]; [@b3]; [@b9]; [@b25]; [@b31]; [@b100]; [@b6]; [@b7]; [@b38]; [@b2]; [@b101]; [@b99]; [@b102]). As for combination regimens, aminoglycosides, quinolones or certain cephalosporin agents in addition to anti-anaerobic medications (clindamycin or metronidazole) also have data to support their use ([@b99]).

Tigecycline has been studied specifically in adult patients with cIAIs in 2 phase III, noninferiority, multicenter, randomized, double-blind trials ([@b77]; [@b45]) and are presented together in a pooled analysis ([@b4]). Patients 18 years old and older who also required surgical intervention for treatment of cIAIs were included. The cIAIs were defined as perforated intestines, intra-abdominal abscesses, appendicitis, diverticulitis, or cholecysitis with perforation and/or abscess with fecal contamination, or perforated gastric/duodenal ulcers, and complicated peritonitis ([@b4]). Patients were stratified by randomization according to their APACHE II scores and received either intravenous tigecycline 100 mg followed by 50 mg every 12 hours or intravenous imipenem-cilastatin 500 mg every 6 hours (adjusted based on the patient's weight and renal function). Patients were generally treated for 5--14 days.

The primary endpoint for these studies was "the clinical response at the test-of-cure visit (12--42 days after therapy) in the co-primary end point microbiologically evaluable \[ME\] and microbiological modified intent-to-treat \[mm-ITT\] populations" ([@b4]).

A total of 1658 patients were randomized in these 2 trials; the mm-ITT population included 1262 patients, and the ME population was composed of 1025 patients. The mean of subject age was 47 years, and the most commonly reported intra-abdominal infection was complicated appendicitis (50.6%, tigecycline and 48.7%, imipenem-cilastatin) followed by complicated cholecystitis (12.8%, tigecycline and 15.1%, imipenem-cilastatin). The average APACHE II score was 6.3 (tigecycline group) and 6 (imipenem-cilastatin) with only 35 patients having an APACHE II score \>15. The mean duration of therapy with either agent was approximately 8 days ([@b4]). Clinical cures were reported in 80.2% (506/631) and 81.5% (514/631) of tigecycline and imipenem m-mITT groups, respectively (% difference (95%CI): −1.3% (−5.8% to 3.2%)). The ME population had similar response rates, with 86.1% (441/512) and 86.2% (442/513) clinical cure rate in the tigecycline and imipenem-cilastatin groups, respectively ([@b4]). Although many organisms were identified, the most commonly isolated organisms included *E. coli* (n = 665)*, S. anginosus* (n = 198), *K. pneumonia* (n = 112) and *B. fragilis* (n = 160) ([@b4]). The most commonly reported adverse events reported in these studies included gastrointestinal complaints with a statistically higher rate in the tigecycline group compared with those receiving imipenem-cilastatin. There were a total of 44.4% and 39.4% of reported adverse events with the digestive system in the tigecycline and imipenem-cilastatin patients, respectively (p = 0.04) ([@b4]).

Based on the results of this analysis, tigecycline appears to be as safe and effective as imipenem in cIAIs. One limitation in this trial was the relatively few resistant organisms isolated. Thus, these studies may not apply to the patient population in which resistance is a concern. Additional clinical trials examining tigecycline's use in cIAIs including resistant organisms will further the utility of tigecycline in this type of infection.

Complicated skin and skin structure infections
----------------------------------------------

Complicated skin and skin structure infections (cSSSIs) either involve deep soft tissues or require surgical debridement or interventions. These infections often require parenteral antimicrobial treatment and frequently occur in patients with other comorbid disease states (such as diabetes or peripheral vascular disease) in which their response to antimicrobial treatment can be suboptimal. Examples of cSSSIs include major abscesses, burns, surgical site infections, diabetic foot, and infected ulcers ([@b20]; [@b73], [@b74]; [@b36]; [@b63]).

Numerous pathogens have been associated with cSSSIs and are often dependent upon the patient and clinical scenario. In general though, *S. aureus* and *Streptococcus* spp. tend to be the predominant pathogens with Gram-negatives, anaerobes, and resistant pathogens such as MRSA becoming more of a factor in immunocompromised patients, injection drug users, and nosocomially-acquired infections ([@b89]; [@b36]). Additionally, some infections (such as lower extremity infections in diabetic patients) tend to be more polymicrobial in nature ([@b37]; [@b89]; [@b36]).

Besides surgical debridement, there are multiple antimicrobial options that are available for the treatment of cSSSIs. Empiric antimicrobial therapy should include coverage for Gram-positive cocci such as staphlococci and streptococci. Additional coverage for Gram-negative organisms, anaerobes (such as *B. fragilis* group), or resistant pathogens is dependent upon patient risk factors for such organisms ([@b73]; [@b36]; [@b105]; [@b63]). Local resistance patterns should also play an important role in deciding appropriate empiric treatment. According to the skin and soft tissue infections guidelines set forth by the Infectious Diseases Society of America ([@b44]; [@b112]; [@b110]; [@b56]; [@b54]; [@b55]; [@b105]; [@b43]; [@b51]), treatment options include broad-spectrum antibiotics such as carbapenems (eg, imipenem/cilastin, meropenem, ertapenem), beta-lactam/beta-lactamase inhibitor combinations (eg, piperacillin-tazobactam, ticarcillin-clavulanate, ampicillin-sulbactam), cephalosporins (eg, cefazolin, cefoxitin), and fluoroquinolones (eg, levofloxacin, moxifloxacin) used alone or in combination with clindamycin or metronidazole for anerobic coverage. The addition of vancomycin or other newer antimicrobial agents (eg, daptomycin, linezolid, quinupristin/dalfopristin, tigecycline) with activity against resistant organisms such as MRSA, VRE, and ESBL-producing gram negative organisms is dependent upon the clinical circumstances of the patient ([@b73]; [@b106]; [@b105]; [@b65]).

Tigecycline has been evaluated for the treatment of cSSSIs in two randomized, multi-centered, double-blind phase 3 studies ([@b16]; [@b41]; [@b94]). In both studies, hospitalized adult patients with cSSSIs (defined as deep soft tissue infections, soft tissue infections requiring surgical debridement, or soft tissue infections in patients with underlying disease such as diabetes or peripheral vascular disease) were randomized (1:1) to receive either tigecycline (100 mg loading dose followed by 50 mg every 12 hours over 60 minutes) or vancomycin (1 g every 12 hours over 60 minutes with adjustments based on renal function) plus aztreonam (2 g every 12 hours over 60 minutes) intravenously for up to 14 days. At the discretion of the investigators, aztreonam therapy could be discontinued after 48 hours of treatment. The clinical response at the test-of-cure-visit (12--92 days after the last dose) in the clinically evaluable (CE) and the clinical modified intention-to-treat (c-mITT) was the primary endpoint of these studies ([@b41]).

Pooled analysis of the data (N = 1129) demonstrated that baseline demographics between each group was similar in terms of type of infection and incidence of other comorbid disease states ([@b41]). Caucasian (68.2%) men (62.1%) with a mean age of 48 made up the majority of the patients enrolled in the studies. Patients were on antibiotic treatment for a mean of 8 days in each group. The most common type of cSSSIs was cellulitis (59%). In the c-mITT analysis (comprised of patients who received at least 1 dose of the study drug and had clinical evidence of a cSSSI; ) (N = 1057), 79.7% in the tigecycline arm (429/538) versus 81.9% in the vancomycin-aztreonam arm (425/519) \[95% CI for the difference −2.1 (−7.1% to 2.8%)\] had a clinical cure, defined as resolution of the signs and symptoms of cSSSI and completion of antibiotic therapy. Clinical cure rates for the CE population (defined as c-mITT population without *P. aeruginosa* as sole isolate, no other concurrent antibiotic therapy, and assessed for failure or cure at the TOC visit) (N = 833) were 86.5% for patients receiving tigecycline (365/422) versus 88.6% in the comparator arm (364/411) \[95% CI for the difference, −2.1 (−6.8 to 2.7)\]. The most common organism isolated was MSSA (N = 254). Cure rates for MSSA were 88.8% (N = 119/134) versus 90.8% (N = 109/120), respectively for tigecycline and vancomycin-aztreonam arms. Sixty-five patients had MRSA isolates, of which 32% (N = 21/65) were considered to be community-acquired strains. Overall cure rates for MRSA were 78.1% (N = 25/32) in the tigecycline arm and 75.8% (N = 25/33) for the vancomycin-aztreonam arm ([@b41]). ESBL-producing organisms treated with tigecycline had clinical cure rates of 77.8% (N = 9) for *E. coli*, 85.7% (N = 7) for *K. pneumoniae*, and 100% (N = 3) for *P. mirabilis* ([@b41]). The authors concluded from these pooled analysis, that tigecycline was noninferior to the combination of vancomycin-aztreonam in the treatment of cSSSIs. The incident of adverse events was similar between the groups (67.7% tigecycline versus 61.1% vancomycin-aztreonam) with the most common adverse events being related to gastrointestinal complaints (46% tigecycline versus 21% vancomycin-aztreonam; p \< 0.001) ([@b41]).

Conclusions
===========

Tigecycline represents a new treatment option for both cSSSIs and cIAIs due, in part, to its favorable in vitro activity against a wide variety of aerobic Gram-positive, Gram-negative and anaerobic organisms (including multidrug-resistant pathogens such as MRSA, VRE, and ESBL-producing strains of *E. coli* and *Klebsiella*). In contrast, tigecycline lacks activity in vitro against *P. aeruginosa* and *P. mirabilis*. Following twice daily intravenous administration, it is extensively distributed to various body tissues and fluids. Dose modification is required in patients with significant hepatic impairment. Because of the metabolic profile of tigecycline, the potential for drug interactions appears to be minimal.

Based on existing clinical efficacy and safety data, tigecycline has been FDA-approved for use as monotherapy for the treatment of cSSSIs and cIAIs. Published clinical efficacy data in humans reports tigecycline as noninferior to comparators for such indications. Tigecycline might be particularly useful in suspected or documented polymicrobial infections, including those patients otherwise requiring combination therapies due to the presence of drug-resistant pathogens such as MRSA, VRE, or ESBL-producing strains of *E. coli* and *K. pneumoniae*. In contrast, its role as part of combination therapy with other antimicrobials is uncertain. Gastrointestinal side effects (mainly nausea) may be problematic in some patients.
